Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross-sectional study

To address the frequency of myelin oligodendrocyte glycoprotein (MOG) antibody (Ab) in an unselected large cohort of adults with MS. This is a cross-sectional study in 2 MS expert centers (Lyon and Strasbourg University Hospitals, France) between December 1, 2017, and June 31, 2018. Patients aged ≥1...

Full description

Saved in:
Bibliographic Details
Published in:Neurology : neuroimmunology & neuroinflammation 2020-03, Vol.7 (2), p.e649-e649
Main Authors: Cobo-Calvo, Álvaro, d'Indy, Hyacintha, Ruiz, Anne, Collongues, Nicolas, Kremer, Laurent, Durand-Dubief, Françoise, Rollot, Fabien, Casey, Romain, Vukusic, Sandra, De Seze, Jérôme, Marignier, Romain
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Autoantibodies - blood
Cross-Sectional Studies
Female
HEK293 Cells
Humans
Life Sciences
Male
Middle Aged
Multiple Sclerosis - blood
Multiple Sclerosis, Chronic Progressive - blood
Myelin-Oligodendrocyte Glycoprotein - immunology
Neurons and Cognition
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To address the frequency of myelin oligodendrocyte glycoprotein (MOG) antibody (Ab) in an unselected large cohort of adults with MS. This is a cross-sectional study in 2 MS expert centers (Lyon and Strasbourg University Hospitals, France) between December 1, 2017, and June 31, 2018. Patients aged ≥18 years with a definite diagnosis of MS according to 2010 McDonald criteria were tested for MOG-Ab by using a cell-based assay (CBA) in Lyon and subsequently included. Positive samples were tested by investigators blinded to the first result with a second assay in a different laboratory (Barcelona, Spain) by using the same plasmid and secondary Ab. Serum samples from 685 consecutive patients with MS were analyzed for MOG-Ab. Median disease duration at sampling was 11.5 (interquartile range, 5.8-17.7) years, and 72% were women. Two (0.3%) patients resulted to be MOG-Ab-positive. The 2 patients were women aged 42 and 38 at disease onset and were diagnosed with secondary and primary progressive forms of MS, respectively. This positive result was confirmed by the CBA in Barcelona. Our findings indicate that MOG-Ab are exceptional in MS phenotype, suggesting that the MOG-Ab testing should not be performed in typical MS presentation.
ISSN:2332-7812
2332-7812
DOI:10.1212/NXI.0000000000000649